The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.

Does the pharmaceutical industry influence guidelines?: two examples from Germany. Dtsch Arztebl Int (2013) 3.78

The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int (2010) 3.36

Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med (2013) 2.49

A survey of german physicians in private practice about contacts with pharmaceutical sales representatives. Dtsch Arztebl Int (2010) 2.19

The effect of a conflict of interest disclosure form using closed questions on the number of positive conflicts of interest declared - a controlled study. PeerJ (2013) 1.49

Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles. PLoS Med (2011) 1.16

Science of weight loss supplements: compromised by conflicts of interest? World J Gastroenterol (2010) 1.02

Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol (2014) 1.00

Medical students' attitudes to and contact with the pharmaceutical industry: a survey at eight German university hospitals. Dtsch Arztebl Int (2013) 0.97

Disclosing conflicts of interest in patient decision aids. BMC Med Inform Decis Mak (2013) 0.86

Conflicts of interest and spin in reviews of psychological therapies: a systematic review. BMJ Open (2016) 0.80

Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review. BMC Med Ethics (2014) 0.80

Randomised trials in context: practical problems and social aspects of evidence-based medicine and policy. Trials (2015) 0.80

The effect of specialized cancer treatment centers on treatment efficacy in Hodgkin's lymphoma. Dtsch Arztebl Int (2012) 0.78

Drug research: marketing before evidence, sales before safety. Dtsch Arztebl Int (2010) 0.76

Correspondence (letter to the editor): National foundation. Dtsch Arztebl Int (2010) 0.75

Correspondence (letter to the editor): Wholesale accusations? Dtsch Arztebl Int (2010) 0.75

Correspondence (letter to the editor): Opinion leaders. Dtsch Arztebl Int (2010) 0.75

Peer review comments on drug trials submitted to medical journals differ depending on sponsorship, results and acceptance: a retrospective cohort study. BMJ Open (2015) 0.75

Correspondence (letter to the editor): Search bias. Dtsch Arztebl Int (2010) 0.75

Correspondence (letter to the editor): Trend gives cause for concern. Dtsch Arztebl Int (2010) 0.75

Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding. BMJ Open (2017) 0.75

Correspondence (letter to the editor): Notorious weaknesses. Dtsch Arztebl Int (2010) 0.75

Correspondence (letter to the editor): Need for advice. Dtsch Arztebl Int (2010) 0.75

[Nothing is more damaging to a new truth than an old error : Conformity of new guidelines on opioid administration for chronic pain with the effect prognosis of the DGSS S3 guidelines LONTS (long-term administration of opioids for non-tumor pain)]. Schmerz (2010) 0.75

Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38

Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (2003) 18.72

Equipoise and the ethics of clinical research. N Engl J Med (1987) 17.24

Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA (2003) 16.08

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA (2003) 8.21

Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA (1999) 7.94

The uncertainty principle and industry-sponsored research. Lancet (2000) 7.75

Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA (1998) 5.99

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med (1994) 5.04

The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med (2008) 4.70

Validation of an index of the quality of review articles. J Clin Epidemiol (1991) 4.54

Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ (2004) 4.53

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ (2006) 4.42

Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA (2006) 3.65

Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum (2007) 3.61

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry (2006) 3.35

Stopping a trial early in oncology: for patients or for industry? Ann Oncol (2008) 3.06

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry (2005) 3.05

End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol (2003) 2.98

Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials (2007) 2.86

Influences on the quality of published drug studies. Int J Technol Assess Health Care (1996) 2.83

Association of funding and findings of pharmaceutical research at a meeting of a medical professional society. Am J Med (2004) 2.83

Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med (2007) 2.36

Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. J Sex Med (2008) 2.25

Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry (2003) 2.25

Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ (2007) 2.15

Results, rhetoric, and randomized trials: the case of donepezil. J Am Geriatr Soc (2008) 2.13

Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother (2004) 2.07

Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther (2004) 2.07

The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract (2001) 1.95

The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. Addiction (2007) 1.92

Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship. Isr Med Assoc J (2006) 1.68

Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer (2007) 1.62

Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br J Clin Pharmacol (2006) 1.43

Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol (2008) 1.33

Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry (2003) 1.27

Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Arch Intern Med (2007) 1.27

Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol (2008) 1.25

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials (2004) 1.22

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer (2005) 1.21

Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry (2007) 1.20

Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med (2006) 1.17

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Can J Psychiatry (2004) 1.14

Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain (2006) 1.12

Extent and impact of industry sponsorship conflicts of interest in dermatology research. J Am Acad Dermatol (2005) 1.09

Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications. Dtsch Arztebl Int (2009) 1.03

Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study. J Am Acad Dermatol (2006) 0.93

Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford) (2008) 0.91

Haematological anticancer drugs in Europe: any added value at the time of approval? Eur J Clin Pharmacol (2007) 0.82

A meta-analysis comparing trials of antimuscarinic medications funded by industry or not. BJU Int (2006) 0.81

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood (2010) 4.17

Does the pharmaceutical industry influence guidelines?: two examples from Germany. Dtsch Arztebl Int (2013) 3.78

The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int (2010) 3.36

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood (2008) 2.68

What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. PLoS One (2012) 2.44

Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev (2012) 2.43

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol (2005) 2.36

Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol (2006) 2.22

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood (2011) 2.14

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol (2009) 2.13

Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood (2006) 2.10

Neural correlates of antinociception in borderline personality disorder. Arch Gen Psychiatry (2006) 1.78

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood (2004) 1.76

Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell (2006) 1.74

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood (2012) 1.73

New drugs: evidence relating to their therapeutic value after introduction to the market. Dtsch Arztebl Int (2012) 1.71

Declaration and Handling of Conflicts of Interest in Guidelines: A Study of S1 Guidelines From German Specialist Societies From 2010-2013. Dtsch Arztebl Int (2015) 1.68

Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66

Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Arch Toxicol (2004) 1.64

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol (2011) 1.61

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica (2012) 1.50

An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results. Am J Psychiatry (2007) 1.50

Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol (2003) 1.49

Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry (2003) 1.48

Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging (2008) 1.48

Self-stigma, empowerment, and perceived legitimacy of discrimination among women with mental illness. Psychiatr Serv (2006) 1.48

Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch Toxicol (2011) 1.46

State affective instability in borderline personality disorder assessed by ambulatory monitoring. Psychol Med (2007) 1.45

Self-stigma in women with borderline personality disorder and women with social phobia. J Nerv Ment Dis (2006) 1.39

High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res (2004) 1.36

Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A (2008) 1.34

Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy (2013) 1.32

Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med (2013) 1.31

Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry (2002) 1.28

Increased nocturnal interleukin-6 excretion in patients with primary insomnia: a pilot study. Brain Behav Immun (2005) 1.26

Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol (2006) 1.24

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom (2008) 1.22

Shame and implicit self-concept in women with borderline personality disorder. Am J Psychiatry (2007) 1.22

Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia (2005) 1.22

Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. Behav Res Ther (2004) 1.19

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol (2003) 1.18

Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev (2010) 1.18

Pharmacokinetics explain in vivo/in vitro discrepancies of carcinogen-induced gene expression alterations in rat liver and cultivated hepatocytes. Arch Toxicol (2012) 1.18

Gender differences in axis I and axis II comorbidity in patients with borderline personality disorder. Psychopathology (2009) 1.16

SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage (2008) 1.16

Affective dysregulation and dissociative experience in female patients with borderline personality disorder: a startle response study. J Psychiatr Res (2005) 1.15

High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood (2009) 1.13

Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs (2005) 1.12

Reliability of three alternate forms of the trail making tests a and B. Arch Clin Neuropsychol (2011) 1.11

Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species. Blood (2005) 1.11

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood (2009) 1.10

Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. J Neuroimmunol (2002) 1.09

Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. Br J Psychiatry (2008) 1.09

Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol (2006) 1.09

XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J (2004) 1.07

Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans' cell sarcoma: evidence for hematopoietic plasticity. Haematologica (2010) 1.07

Bisphenol A levels in blood depend on age and exposure. Toxicol Lett (2009) 1.06

Epidural venous enlargements presenting with intractable lower back pain and sciatica in a patient with absence of the infrarenal inferior vena cava and bilateral deep venous thrombosis. Spine (Phila Pa 1976) (2007) 1.06

NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica (2013) 1.06

Deep brain stimulation for treatment of refractory depression. Lancet (2005) 1.06

Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain (2004) 1.04

GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology (2011) 1.04

Elevated pain thresholds correlate with dissociation and aversive arousal in patients with borderline personality disorder. Psychiatry Res (2006) 1.04

Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol (2007) 1.03

Increased delta power and discrepancies in objective and subjective sleep measurements in borderline personality disorder. J Psychiatr Res (2005) 1.02

In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer (2006) 1.02

Measuring shame and guilt by self-report questionnaires: a validation study. Psychiatry Res (2007) 1.01

Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer (2008) 1.01

Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. Neuropharmacology (2011) 1.00

Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia (2008) 1.00

The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.98

Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci (2014) 0.98

Life context of pharmacological academic performance enhancement among university students--a qualitative approach. BMC Med Ethics (2014) 0.98

Correlation of protein expression and gene expression in acute leukemia. Cytometry B Clin Cytom (2003) 0.96

Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest (2003) 0.96

Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol (2008) 0.96

Extraction of prefronto-amygdalar pathways by combining probability maps. Psychiatry Res (2009) 0.94

High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol (2007) 0.94

A coordinate-based ALE functional MRI meta-analysis of brain activation during verbal fluency tasks in healthy control subjects. BMC Neurosci (2014) 0.94

Psychological interventions for antisocial personality disorder. Cochrane Database Syst Rev (2010) 0.94

Neural correlates of interference inhibition, action withholding and action cancelation in adult ADHD. Psychiatry Res (2012) 0.93

Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia. Clin Cancer Res (2006) 0.93

Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. Neuroimage (2007) 0.93

Risk assessment of Bundeswehr (German Federal Armed Forces) permethrin-impregnated battle dress uniforms (BDU). Int J Hyg Environ Health (2008) 0.93

[Characteristics of university students using stimulants for cognitive enhancement: a pilot study]. Psychiatr Prax (2012) 0.92

In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood (2002) 0.91

Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. Haematologica (2011) 0.90

The impact of posttraumatic stress disorder on dysfunctional implicit and explicit emotions among women with borderline personality disorder. J Nerv Ment Dis (2007) 0.90

Time course of anger and other emotions in women with borderline personality disorder: a preliminary study. J Behav Ther Exp Psychiatry (2007) 0.90